Lixian Wu Wu | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Prof. Lixian Wu Wu | Pharmacology | Best Researcher Award

Vice Dean at Fujian Medical University, China.

Dr. Lixian Wu 🎓 is an accomplished pharmacologist from Fujian, China, with over 20 years of experience in anticancer drug research 💊. Her groundbreaking work includes DNA repair mechanisms 🧬, tumor microenvironment interactions 🧫, and PROTAC-based drug design 🧪. A distinguished researcher and mentor, she has led multiple national projects 📑, secured five patents 📘, and published influential scientific papers 📚. As a doctoral advisor, she has guided numerous Ph.D. and master’s students 🎓. Dr. Wu’s dedication to innovation and excellence has earned her the title of Fujian Provincial High-Level Talent 🌟.

Professional Profile:

Scopus

Suitability for Best Researcher Award – Dr. Lixian Wu

Dr. Lixian Wu is highly suitable for the Best Researcher Award due to her sustained excellence in anticancer pharmacology research, innovative drug discovery, and academic mentorship over the past two decades. Her ability to translate complex molecular mechanisms into potential therapeutic strategies—such as PROTAC-based compounds and immune-targeted therapies—demonstrates a deep and ongoing commitment to impactful, high-quality science. She has also contributed significantly to China’s biomedical innovation ecosystem through patents, national-level research leadership, and talent cultivation.

🎓 Education & Experience

  • 🎓 Bachelor’s Degree in Clinical Medicine – Fujian Medical University, China

  • 🧪 Master’s Degree (M.D.) in Pharmacology – Fujian Medical University

  • 🧬 Ph.D. in Pharmacology – Fujian Medical University

  • 🧠 20+ years of research experience in anticancer pharmacology

  • 🧑‍🏫 Doctoral Tutor mentoring 8 Ph.D. and 20 Master’s students

  • 📋 Principal Investigator for 4 National Natural Science Foundation projects

📈 Professional Development 

Dr. Wu has continually advanced her professional journey through innovative research and academic leadership 🌐. She has synthesized and screened high-efficacy anticancer compounds via PROTAC technology 🧪, explored immune-based cancer therapy through NKT cell modulation 🔬, and discovered novel feedback loops in DNA repair pathways 🧬. She remains actively engaged in national-level scientific funding programs 📑 and contributes to the field through patents and impactful publications 📚. Her mentorship has nurtured the next generation of pharmacologists 👩‍🔬👨‍🔬, enhancing China’s scientific landscape. Her evolving research and professional expertise position her as a thought leader in oncology drug discovery 🌟.

🧪 Research Focus Category

Dr. Wu’s research primarily centers on anticancer pharmacology 💊, particularly the molecular mechanisms of cancer progression and therapy 🧬. Her work targets DNA repair pathways, unveiling the regulatory roles of NF-kB and PARP1 in tumor survival 🔍. She also explores the tumor microenvironment, focusing on the immune system’s role in fighting cancer, especially through NKT cells 🧫. Leveraging PROTAC technology, she has developed degradation-based drug strategies with high therapeutic potential ⚗️. Her multi-dimensional approach places her research at the crossroads of immunopharmacology, molecular biology, and drug design, making a significant impact on cancer therapeutics 🔬.

🏅 Awards and Honors

  • 🏆 Fujian Provincial High-Level Talent recognition

  • 📑 Principal Investigator of 4 National Natural Science Foundation of China (NSFC) grants

  • 🧪 Holder of 5 Chinese Invention Patents in anticancer drug development

  • 📚 Author of several influential SCI-indexed research papers

  • 🎓 Mentor to 8 Ph.D. and 20 Master’s students

Publication Top Notes

🧬 Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma – iScience (2024) | Cited by: 1

💊 Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles – Journal of Controlled Release (2024) | Cited by: 22

🔬 Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer – European Journal of Medicinal Chemistry (2023) | Cited by: 5

🧪 Synthesis of Novel Dual Target Inhibitors of CDK12 and PARP1 and Their Antitumor Activities in HER2-Positive Breast Cancers – ACS Omega (2023) | Cited by: 3

Conclusion

Dr. Lixian Wu exemplifies the qualities of a Best Researcher Award recipient through her innovative research, national and international impact, and mentorship leadership. Her contributions to anticancer drug design and her role in shaping China’s research capacity place her in the top tier of biomedical researchers. She is not only a leader in her field but also a beacon for emerging scientists in pharmacology.

Mr. Mehmet Onur Yağır | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Mr. Mehmet Onur Yağır | Pharmacology | Best Researcher Award

Mr. Mehmet Onur Yağır ,Sakarya University,Turkey

Mehmet Onur Yağır is an experienced engineer with a robust background in mechanical and electrical engineering. Currently serving as a Teaching Assistant at Sakarya University and an Assistant Manager at Adapazarı Vocational High School, he brings a wealth of knowledge from his 13-year tenure as Chief of Mechanical R&D at Federal Electric. Mehmet is pursuing a PhD in Manufacturing Engineering at Sakarya University, following his Master’s and Bachelor’s degrees in Mechanical Engineering and Electrical and Electronics Engineering from the same institution. Proficient in Unigraphics and SolidWorks, he also has skills in Pro-Engineer, Catia, Matlab, Proteus, Arduino, FluidSim, Maxwel, and C# programming.

Professional Profile:

Orcid

Suitability for Best Researcher Award:

Mehmet Onur Yağır’s combination of extensive industry experience, robust academic background, and diverse technical skills makes him a compelling candidate for the Best Researcher Award. His achievements in mechanical and electrical engineering, coupled with his commitment to advancing research through his PhD studies, position him as an influential figure in engineering research and development.

🎓Education:

Mehmet Onur Yağır holds a diverse and extensive educational background, all from Sakarya University. He is currently pursuing a PhD in Manufacturing Engineering, a program he began in 2021. Previously, he completed his Master’s Degree in Mechanical Engineering at Sakarya University from September 2007 to October 2015. He also earned dual Bachelor’s Degrees in Mechanical Engineering and Electrical and Electronics Engineering, both from Sakarya University, graduating in June 2006.

🏢Work Experience:

Mehmet Onur Yağır has a distinguished career with significant roles in both academia and industry. Since 2019, he has served as a Teaching Assistant at Sakarya University and as an Assistant Manager at Adapazarı Vocational High School. Prior to these positions, he spent 13 years as the Chief of Mechanical R&D at Federal Electric, where he led critical research and development initiatives from 2006 to 2019.

Publication Top Notes:

Title: Examination of Various Abutment Designs Behavior Depending on Load Using Finite Element Analysis

 

 

Prof. Dr. Yukihiko Sugimoto | Pharmacology Awards | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Yukihiko Sugimoto | Pharmacology Awards | Best Researcher Award

Prof. Dr. Yukihiko Sugimoto,Kumamoto University Graduate School of Pharmaceutical Sciences,Japan

Yukihiko Sugimoto is a distinguished biochemist currently serving as a Professor of Biochemistry at Kumamoto University, Japan. Born on November 20, 1965, in Kyoto, Japan, he earned his Ph.D. from Kyoto University in 1994 with a thesis on prostaglandin E receptors. His research, which spans over three decades, focuses on the biochemical and physiological roles of prostaglandins and their receptors. Professor Sugimoto has been recognized with several prestigious awards, including the Young Scientist Award from both The Japanese Pharmacological Society and The Japanese Biochemical Society. His notable publications include influential papers on the role of prostaglandins in various biological processes and diseases.

Professional Profile:

Scopus

Orcid

Summary of Suitability:

Yukihiko Sugimoto stands out as a strong candidate for the Research for Best Researcher Award due to his substantial contributions to the field of biochemistry and pharmacology. His extensive research portfolio, spanning over three decades, showcases significant advancements in understanding prostaglandin receptors and their implications in various physiological and pathological processes.

🎓Education:

Professor Yukihiko Sugimoto completed his undergraduate studies in Pharmaceutical Sciences at the Faculty of Pharmaceutical Sciences, Kyoto University, from 1984 to 1988. He then pursued a Master’s degree in Pharmaceutical Sciences at the Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, between 1988 and 1990. Following this, he obtained his Ph.D. in 1994 from the same department, with his thesis focusing on “A Study for Structure and Function of Prostaglandin E Receptors,” under the supervision of Professor Atsushi Ichikawa

🏢Work Experience:

Professor Yukihiko Sugimoto began his academic career as an Assistant Professor of Physiological Chemistry at Kyoto University, where he worked from 1992 to 1997. He then advanced to the role of Associate Professor of Physiological Chemistry at the same institution, serving from 1997 to 2009. Since 2009, he has been a Professor of Biochemistry at Kumamoto University, continuing his influential research and contributions to the field.

🏅Awards:

Professor Yukihiko Sugimoto has received notable recognition for his contributions to the field of biochemistry. He was honored with the Young Scientist Award by The Japanese Pharmacological Society in 1999 and again by The Japanese Biochemical Society in 2005. These awards acknowledge his significant research achievements and impact on the scientific community.

Publication Top Notes:

  • “The Concise Guide to PHARMACOLOGY 2023/24: G Protein-Coupled Receptors”
    • Citations: 89
  • “Prostaglandin E2 Receptor Ptger4b Regulates Female-Specific Peptidergic Neurons and Female Sexual Receptivity in Medaka”
    • Citations: 2
  • “Metabolic Regulation in Adipocytes by Prostanoid Receptors”
  • “Effects of an ω3 Fatty Acid-Biased Diet on Luteolysis, Parturition, and Uterine Prostanoid Synthesis in Pregnant Mice”
    • Citations: 1
  • “Amakusamine from a Psammocinia sp. Sponge: Isolation, Synthesis, and SAR Study on the Inhibition of RANKL-Induced Formation of Multinuclear Osteoclasts”
    • Citations: 8

 

 

 

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Posted on by ScienceFather

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Prof. Franciska Erdo , Pázmány Péter Catholic University , Hungary

Franciska Vidáné Dr. Erdő, born on May 28, 1964, in Budapest, is a distinguished full professor and lab head at Pázmány Péter Catholic University, Faculty of Information Technology and Bionics. She holds a PhD in pharmacology from Semmelweis University and has extensive experience in both academic and research institutions, including the University of Tours, Charité Medizinische Universität in Berlin, and the Max-Planck Institute in Cologne. Her research focuses on drug research and development, evidenced by her numerous fellowships and scholarships. She has supervised over 31 graduate students and postdoctoral fellows and has been recognized for her teaching excellence. Dr. Erdő has also contributed significantly to scientific literature and education, particularly in the fields of molecular bionics and biomedical innovation.

Professional Profile:

Orcid

Education:

Franciska Vidáné Dr. Erdő earned her MSc in Pharmacy from Semmelweis University in 1987, graduating with top grades. She continued her education at the same institution, achieving a University Doctor degree in Pharmacology with summa cum laude honors in 1994. In 1997, she completed her PhD in Pharmacology, also with summa cum laude distinction, at Semmelweis University, Faculty of Pharmacy. Most recently, in 2019, she received her habilitation from Pázmány Péter Catholic University, Faculty of Information Technology and Bionics.

Work Experience:

Franciska Vidáné Dr. Erdő has held numerous esteemed positions throughout her career. Since 2024, she has been serving as a Full Professor and Lab Head at Pázmány Péter Catholic University, Faculty of Information Technology and Bionics. Prior to this, from 2019 to 2024, she was an Associate Professor and Lab Head at the same institution. She was also a Guest Researcher at the University of Tours, France, in 2022. From 2014 to 2019, she worked as a Senior Research Fellow and Lab Head at Pázmány Péter Catholic University. Her earlier roles include serving as a Senior Research Fellow and Lab Head at SOLVO Biotechnology from 2007 to 2014, and holding a scientific scholarship at Charité Medizinische Universität in Berlin, Germany, from 2005 to 2006. She also worked as a Senior Research Fellow at IVAX Drug Research Institute from 2003 to 2007 and held a Max Planck Fellowship at the Max-Planck Institute für neurologische Forschung in Cologne, Germany, from 2000 to 2003. Her earlier positions include Senior Research Fellow roles at Sanofi-Synthelabo Chinoin from 1997 to 2000 and Biorex R&D Co. from 1995 to 1997. She began her career as a Research Fellow at the Institute for Drug Research from 1990 to 1995 and as a Junior Research Fellow at the same institute from 1987 to 1990.

Publication Top Notes:

1.Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

  • Journal: Scientia Pharmaceutica
  • Publication Date: June 2024

2. Progress in Topical and Transdermal Drug Delivery Research—Focus on Nanoformulations

  • Journal: Pharmaceutics
  • Publication Date: June 2024

3. Transdermal Delivery of α-Aminophosphonates as Semisolid Formulations—An In Vitro-Ex Vivo Study

  • Journal: Pharmaceutics
  • Publication Date: May 2023